Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
SEDPARK1: Safety and Efficacy Study With the Non-Ergot Dopamine-Agonist Piribedil in Parkinson's Disease (PIR-001/K)
This study has been completed.
Study NCT00725478. Last updated on August 7, 2008.
Information provided by Desitin Arzneimittel GmbH
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Parkinson's Disease
Additional conditions recognized in this trial
Parkinson Disease
More general conditions related to this trial
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders
Interventions listed in this trial
Piribedil
Additional drug interventions recognized in this trial
Dopamine
Dopamine Agonists
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Antiparkinson Agents
Autonomic Agents
Cardiotonic Agents
Cardiovascular Agents
Central Nervous System Agents
Dopamine Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Sympathomimetics
Therapeutic Uses
Sponsors listed in this trial
Desitin Arzneimittel GmbH
Back to top of Main Content